Can Investigational Drug Reduce Persistent Ebola Viral in Semen
Monrovia — The Liberia-U.S. Clinical Research Partnership known as PREVAIL today announced the start of a new study in male survivors of Ebola at the JFK Medical Center in Sinkor. The study–called PREVAIL IV, or the Persistent Ebola Virus Study–is designed to find out if an investigational drug called GS-5734 can safely get rid of or reduce the amount of Ebola viral RNA that may persist in the semen of some male Ebola survivors.
The Ebola viral RNA may stay hidden in certain parts of the body and body fluids, such as semen, even after a person recovers from Ebola. This is called persistent Ebola viral RNA. The virus can persist because the body’s immune system cannot easily reach and fight off the virus that is hiding in these protected places.
“Our experience with traditional public health measures to contain Ebola has proven effective”, said Tolbert Nyenswah, Head of Liberia’s (Ebola) Incident Management Systems and Deputy Minister of Heath. “However, there are still unanswered questions with Ebola therefore an attempt to address residual and persistent virus through PREVAIL IV study is critical”, he added.